Phase 1 Diagnostic Tests
The Biosensor Platform uses Organic Thin Film Transistor (OTFT) technology, which can be printed at scale, at a low cost. By substituting the detection element (region A) depending on the analyte to be detected, the Biosensor can be modified to monitor a wide range of saliva-based diagnostic analytes . The Platform is in development to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases.
Currently, we are developing two urgently needed innovations using the Biosensor Platform.
Future Pipeline
IMMUNOLOGY
The pilot diagnostic test will be SARS-CoV-2 and the portfolio will consist of various communicable disease tests including Hepatitis A, B & C, HIV and TORCH.
HORMONES
The first test to be developed from a hormone category is Luteinizing Hormone (LH).
BIOCHEMISTRY
The pilot diagnostic test is Saliva Glucose. Diagnostic test portfolio includes Clinical Chemistry Tests (ie. Cholesterol).
TUMOR MARKERS
Tumor markers can be used in guiding treatment decisions, monitoring treatment, predicting the chance of recovery, and predict or monitor for tumor recurrence.
BIOSENSOR PLATFORM
BIOCHEMISTRY
TUMOR MARKERS
IMMUNOLOGY
HORMONES
NUCLEIC ACIDS
PORTFOLIO
– Immunology Tests
-TORCH
– HIV, AIDS,
– Hep A,B & C
– Adrenal
– Pituitary
– Gyncecological
– Andrology
DIAGNOSTIC TEST
DIAGNOSTIC TEST
BIOSENSOR PLATFORM
DIAGNOSTIC TEST
PORTFOLIO
BIOCHEMISTRY
Clinical Chemistry Tests (i.e. Cholesterol)
TUMOR MARKERS
Diagnostic and Staging Cancer Markers
IMMUNOLOGY
– Clinical
– Immunology Tests
-TORCH
– HIV, AIDS,
– Hep A,B & C
HORMONES
– Thyroid
– Adrenal
– Pituitary
– Gyncecological
– Andrology
NUCLEIC ACIDS
Personalized Genetic Diagnostics
PHASE 2
DIAGNOSTIC TEST
BIOCHEMISTRY
–
TUMOR MARKERS
Prostate Specific Antigen (PSA)
IMMUNOLOGY
–
HORMONES
Luteinizing Hormone (LH)
NUCLEIC ACIDS
–
PHASE 1
DIAGNOSTIC TEST
BIOCHEMISTRY
Saliva Glucose Test
TUMOR MARKERS
–
IMMUNOLOGY
SARS-CoV-2 Antibodies
HORMONES
–
NUCLEIC ACIDS
–